drugset
drugset / Trial / NCT01359696

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

NCT01359696 ↗

Phase 1 Completed 40 enrolled Genentech, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with and without gemcitabine.

Timeline

Start
2011-07-11
Primary completion
2014-05-29
Completion
2014-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — Intravenous
Subject RG-7602 Small molecule — Oral

Indications

cancer